Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
72,987,327
-
Number of holders
-
90
-
Total 13F shares, excl. options
-
42,272,843
-
Shares change
-
+14,256,672
-
Total reported value, excl. options
-
$169,997,165
-
Value change
-
+$59,022,508
-
Number of buys
-
52
-
Number of sells
-
32
-
Price
-
$4.02
Institutional Holders of Lexeo Therapeutics, Inc. - Common Stock (LXEO) as of Q2 2025
As of 30 Jun 2025 Lexeo Therapeutics, Inc. - Common Stock (LXEO) had 90 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 42,272,843 shares of stock of the company.
Largest 10 holders included Frazier Life Sciences Management, L.P., Balyasny Asset Management L.P., JANUS HENDERSON GROUP PLC, CITADEL ADVISORS LLC, Affinity Asset Advisors, LLC, Vestal Point Capital, LP, MILLENNIUM MANAGEMENT LLC, Woodline Partners LP, VANGUARD GROUP INC, and BlackRock, Inc..
This table shows 90 institutional shareholders of the security as of 30 Jun 2025.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.